Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554333 | 0.85 | GPR88 (0.54) | GPR88CA1CA2ACHEATM | |
| SCHEMBL13899543 | 0.83 | ATM (0.46) | GPR88ATMITGB3ITGA2BTACR1 | |
| SCHEMBL1554043 | 0.82 | CA1 (0.47) | GPR88CA1CA2ACHEATM | |
| SCHEMBL1554726 | 0.79 | GPR88 (0.52) | GPR88ATM | |
| SCHEMBL13899365 | 0.77 | ATM (0.46) | ATMITGB3ITGA2BTACR1 | |
| SCHEMBL13536743 | 0.75 | ALDH1A1 (0.52) | ITGB3ITGA2BTACR1MEN1KMT2A | |
| SCHEMBL13899285 | 0.75 | AAK1 (0.49) | ATMMEN1KMT2AAAK1 | |
| SCHEMBL1701856 | 0.75 | ITGB3 (0.67) | ITGB3ITGA2BTACR1 | |
| SCHEMBL12052784 | 0.75 | ITGB3 (0.67) | ITGB3ITGA2BTACR1 | |
| SCHEMBL13721611 | 0.74 | ATM (0.57) | CA1CA2ACHEATMITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2486030-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2486030-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-06 | — | — | US | disclosed |
| WO-2011044195-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | GPR88 1/4885CA1 4614/4885CA2 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.